<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455675</url>
  </required_header>
  <id_info>
    <org_study_id>PsAer-IgY</org_study_id>
    <nct_id>NCT01455675</nct_id>
  </id_info>
  <brief_title>Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients</brief_title>
  <acronym>PsAer-IgY</acronym>
  <official_title>Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mukoviszidose Institut gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mukoviszidose Institut gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa
      after successfully treated acute or intermittent infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double -blind, placebo controlled study in which the investigational drug and the
      reference placebo group are gargled and swallowed. 70 ml IgY/ placebo solution is gargled
      every night for two minutes (for maximal 24 months) The design will include the recruitment
      of 144 patients randomized in two groups (72 per treatment group) In order to compensate for
      dropouts (i.e. patients dropping out prior to 24 months without having an event) the total
      sample size was planned to be approximately 180 (i.e. ~20 % dropout rate). After the actual
      drop-out rate has been low throughout the study, only 144 plus approx. 10% potential
      drop-outs were included into the study.

      During the two years of treatment, subjects will be examined at the clinic every 3 months
      regarding safety and efficacy of the medication.

      For more information please see www.impactt.eu The IMPACTT Project is funded by EU within the
      Framework 7 Program. PsAer-IgY Studies is part of IMPACTT Project (Workpackage 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 27, 2017</completion_date>
  <primary_completion_date type="Actual">June 27, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start of treatment (=Day 0) to the first recurrence of PA (Pseudomonas aeruginosa) in the sputum or throat cough swab or endolaryngeal suction</measure>
    <time_frame>max. 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Change in FEV 1.0 from day 0 to each visit</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in BMI from day 0 to each visit</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Number of exacerbations</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Number of days of illness in hospital and at home, i.e. out of school or work</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Control of use of antibiotics, especially anti-pseudomonas antibiotics -measured as days with antibiotic treatment</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in values of serologic tests for PA precipitins from day 0 to each visit (if applicable)</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Good tolerability and comparable number and quality of adverse events like placebo group</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Sputum or throat cough swab or endolaryngeal suction cultures for bacteria and fungi</measure>
    <time_frame>max. 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>IgY, gargling solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, gargling solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>70 ml gargling solution without antibodies, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IgY</intervention_name>
    <description>Avian polyclonal anti-pseudomonas antibodies (IgY)</description>
    <arm_group_label>IgY, gargling solution</arm_group_label>
    <other_name>PsAer-IgY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 70 ml gargling solution, once daily</description>
    <arm_group_label>Placebo, gargling solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CF patients diagnosed according to specific clinical features and either a positive
             sweat chloride in double proofs or presence of disease-associated CFTR mutations in
             both alleles

          -  Males and females 5 years of age and above (being able to gargle)

          -  CF patients having a FEV1 value between 50% and 130% of predicted value (according to
             Knudson formula)

          -  CF patients who have had one to several sputum or throat cough swabs or endolaryngeal
             suction cultures positive for PA within the last three years and for whom PA has been
             successfully eradicated.

          -  Sputum / throat cough swab/ endolaryngeal suction culture negative for PA and other
             gram-negative bacteria on study entry.

          -  Patients and/ or their legal representative who are willing and able to give informed
             consent/ assent to participate in the study after thorough information

          -  Subjects of child bearing potential and who are sexually active must meet the
             contraception requirements (i.e. oral or injectable contraceptives, intrauterine
             devices, double-barrier method, contraceptive patch, male partner sterilization or
             condoms).

        Exclusion Criteria:

          -  Microbiologic or serologic evidence of chronic infection with PA. Definition of
             chronic PA infection: Three cultures (sputum or throat cough swabs or endolaryngeal
             suction) have been positive for PA for 6 consecutive months (at least 3 cultures have
             to be taken) or more, .

          -  Patients, who have positive sputum culture or throat cough swab or endolaryngeal
             suction culture for gram-negative bacteria, such as PA, S. maltophilia, B. cepacia, A.
             xylosoxidans (eradication before entry in study is possible), Patients, who have
             positive sputum culture or throat cough swab or endolaryngeal suction culture for
             atypical Mycobacteria and / or Aspergillus fumigates, associated with clinical
             symptoms that may necessitate specific treatment.

          -  History of allergy/hypersensitivity to hens' egg proteins (including medication
             allergy) that is deemed relevant to the trial by the investigator. &quot;Relevance&quot; in this
             context refers to any increased risk of hypersensitivity reaction to trial medication.

          -  Patient with a known relevant substance abuse, including alcohol or drug abuse.

          -  Start of a new concomitant or chronic medication for CF within 4 weeks before
             inclusion.

          -  Clinically relevant diseases or medical conditions other than CF or CF-related
             conditions that, in the opinion of the investigator, would compromise the safety of
             the patient or the quality of the data. This includes, but is not limited to,
             significant hematological, hepatic, renal, cardiovascular, and neurological diseases
             (diabetic patients may participate if their disease is under good control prior to
             inclusion).

          -  Participation in another study with an investigational drug within one month or 6
             half-lives (whichever is greater) preceding the inclusion.

          -  The patient is an employee of the investigator or the institution with direct
             involvement in the trial or other trials under the direction of the investigator or
             their members.

          -  Patients who are pregnant cannot be included into the study. This will be tested at
             inclusion visit with a urine pregnancy test (in female patients older than 10 years
             with secondary sexual characteristics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antje Schuster, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck Department für Kinderheilkunde, Päd III CF Zentrum</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(SALK) Universitätsklink für Kinder- und Jugendheilkunde, Ambulanz für Allergien und Lungenerkrankungen</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pediatric Respiratory Diseases, Infectious Diseases and Travel Clinic</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Erasme, Service de Pneumologie</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven, Kindergeneeskunde</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Christiane Herzog Zentrum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ruhr Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang- Goethe Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MH Hannover (adults)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MH Hannover (children)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Jena, Mukoviszidosezentrum</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pal Hospital for Children</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulm. Intézet, XIX. J fsz. Kronikus-CF care</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady´s Children´s Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallagh Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Western Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Regionale Toscano di Riferimento per la Fibrosi Cistica</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ospedale Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Regionale Fibrosi Cisica Lazio</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Dzieciecy Polanki im. Macieja Plazynskiego w Gdansku sp Z o.o. Poradnia Leczenia</name>
      <address>
        <city>Gdansk</city>
        <zip>80-308</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Karpacz Spólka Akcyjna</name>
      <address>
        <city>Karpacz</city>
        <zip>58-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Sanatorium Cassia Villa Medica</name>
      <address>
        <city>Rabka - Zdrój</city>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Matki i Dziecka Zaklad Mukowiscydozy</name>
      <address>
        <city>Warsaw</city>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. M.Kopernika Ośrodek Pediatryczny im. dr J.Korczaka</name>
      <address>
        <city>Łódź</city>
        <zip>90-329</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces Neumologia, Pediatric pulmonology</name>
      <address>
        <city>Barakaldo (Vizcaya)</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Passeig Vall d´Hebron 119</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil la Paz Sección de Neumologia Pediátrica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Materno-Infantil Servicio de Pediatria</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Huddinge - CF-Centre</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Childrens Hospital, Akademiska sjukhuset, CF center</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.impactt.eu</url>
    <description>Information about the IMPACTT project IgY-study is part of</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

